Sarepta Therapeutics, Inc. Aktie News
18,23 €
0,58 %
gestern
L&S,
15. Dezember, 22:54 Uhr
Index
Industrie
tracken
Sarepta Therapeutics, Inc. Aktie News
Negativ
Schaeffers Research
●
etwa ein Monat alt
Sarepta Pharmaceuticals Inc (NASDAQ: SRPT) stock is plummeting down, down 31.4% at $16.77 at last glance.
Negativ
Invezz
●
etwa ein Monat alt
Sarepta Therapeutics Inc. shares plunged 37% on Tuesday after the biotechnology company reported disappointing trial results for two of its treatments targeting Duchenne muscular dystrophy (DMD). The stock fell to $15.28 on Tuesday's open, compounding a steep 80% decline in 2025 before the latest selloff.
Negativ
Barrons
●
etwa ein Monat alt
The biotechnology company discloses disappointing trial data for two treatments for Duchenne muscular dystrophy.
Neutral
Seeking Alpha
●
etwa ein Monat alt
Sarepta Therapeutics, Inc. ( SRPT ) Q3 2025 Earnings Call November 3, 2025 4:30 PM EST Company Participants Tamara Thornton Douglas Ingram - CEO & Director Louise Rodino-Klapac - President of Research & Development and Technical Operations Patrick Moss - Executive VP & Chief Commercial Officer Ryan Wong - Executive VP & CFO Conference Call Participants Anupam Rama - JPMorgan Chase & Co, Researc...
Negativ
Reuters
●
etwa ein Monat alt
Shares of Sarepta sank 36% before the bell on Tuesday after a trial for two gene-targeted therapies for a muscle-wasting disease missed a key goal, deepening concerns about the company's treatment pipeline.
Negativ
Market Watch
●
etwa ein Monat alt
Sarepta's stock sank after studies of Duchenne muscular dystrophy treatments failed their primary endpoints.
Negativ
Reuters
●
etwa ein Monat alt
Sarepta said on Monday that its late-stage study testing two gene-targeted therapies for Duchenne muscular dystrophy did not meet the main goal.
Negativ
Investors Business Daily
●
etwa ein Monat alt
Sarepta stock crashed late Monday after the biotech company said two of its muscular dystrophy drugs failed their confirmatory studies.
Kostenlos registrieren
aktien.guide ist das Tool zum einfachen Finden, Analysieren und Beobachten von Aktien. Lerne von erfolgreichen Investoren und triff fundierte Anlageentscheidungen. Wir machen Dich zum selbstbestimmten Investor.
